^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vizimpro (dacomitinib)

    i
    Company:
    Pfizer, SFJ Pharma
    Drug class:
    pan-HER inhibitor
    Related drugs:
    Apply
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. (NCT06075615)
    Phase N/A
    Pfizer
    Withdrawn
    Last update posted :
    02/07/2025
    Initiation :
    09/30/2024
    Primary completion :
    09/07/2026
    Completion :
    09/07/2026
    EGFR
    |
    EGFR mutation
    |
    Vizimpro (dacomitinib)
    Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) (NCT04155541)
    Phase N/A
    Pfizer
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/24/2020
    Primary completion :
    08/25/2026
    Completion :
    08/25/2026
    EGFR
    |
    EGFR mutation
    |
    Vizimpro (dacomitinib)
    Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (NCT03810807)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/17/2019
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Vizimpro (dacomitinib)
    Korea Post Marketing Surveillance (PMS) Study of Vizimpro (NCT04721106)
    Phase N/A
    Pfizer
    Enrolling by invitation
    Last update posted :
    02/04/2025
    Initiation :
    03/07/2021
    Primary completion :
    03/01/2026
    Completion :
    03/30/2026
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Vizimpro (dacomitinib)
    Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review (ARIA) (NCT04609319)
    Phase N/A
    Pfizer
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    01/23/2021
    Primary completion :
    06/04/2024
    Completion :
    10/08/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Vizimpro (dacomitinib)
    Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations (NCT04511533)
    Phase 4
    Pfizer
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    08/27/2020
    Primary completion :
    10/15/2022
    Completion :
    11/08/2022
    EGFR
    |
    EGFR mutation
    |
    Vizimpro (dacomitinib)
    ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. (ARCHER 1050) (NCT01774721)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    11/14/2023
    Initiation :
    05/09/2013
    Primary completion :
    07/29/2016
    Completion :
    01/27/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    gefitinib • Vizimpro (dacomitinib)
    PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer (NCT01000025)
    Phase 3
    NCIC Clinical Trials Group
    Completed
    Last update posted :
    08/22/2023
    Initiation :
    12/23/2009
    Primary completion :
    01/15/2014
    Completion :
    11/27/2015
    EGFR • KRAS
    |
    EGFR mutation • KRAS wild-type
    |
    cisplatin • Vizimpro (dacomitinib)
    A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. (NCT03755102)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    07/12/2023
    Initiation :
    11/21/2018
    Primary completion :
    07/07/2023
    Completion :
    07/07/2023
    EGFR
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Vizimpro (dacomitinib)
    First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations (NCT05271916)
    Phase 1/2
    Shanghai Chest Hospital
    Recruiting
    Last update posted :
    04/19/2023
    Initiation :
    10/13/2022
    Primary completion :
    01/01/2025
    Completion :
    05/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Focus V (anlotinib) • Vizimpro (dacomitinib)
    Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) (NCT04811001)
    Phase 2
    Fondazione Ricerca Traslazionale
    Recruiting
    Last update posted :
    02/21/2023
    Initiation :
    06/12/2020
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    EGFR • HER-2 • BRAF • ALK • MET • ROS1
    |
    EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
    |
    Tagrisso (osimertinib) • Vizimpro (dacomitinib)
    A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) (NCT01920061)
    Phase 1b
    Pfizer
    Completed
    Last update posted :
    09/13/2022
    Initiation :
    09/10/2013
    Primary completion :
    01/08/2020
    Completion :
    01/08/2020
    HER-2 • KRAS • BRAF
    |
    BRAF V600E • KRAS mutation • BRAF mutation
    |
    cisplatin • docetaxel • Vizimpro (dacomitinib) • gedatolisib (PF-05212384)
    Central Nervous System(CNS) Efficacy of Dacomitinib (NCT04675008)
    Phase 2
    Samsung Medical Center
    Recruiting
    Last update posted :
    01/05/2021
    Initiation :
    12/07/2020
    Primary completion :
    09/01/2022
    Completion :
    03/01/2023
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    Vizimpro (dacomitinib)
    Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer (NCT00553254)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    10/19/2020
    Initiation :
    02/05/2008
    Primary completion :
    08/03/2010
    Completion :
    07/17/2014
    HER-2 • KRAS
    |
    EGFR mutation • HER-2 mutation • KRAS wild-type
    |
    erlotinib • gefitinib • Vizimpro (dacomitinib)
    PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib (NCT00548093)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    05/21/2019
    Initiation :
    04/29/2008
    Primary completion :
    03/16/2010
    Completion :
    06/11/2012
    EGFR • HER-2 • KRAS
    |
    KRAS mutation
    |
    erlotinib • Vizimpro (dacomitinib)
    Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (ARCHER 1042) (NCT01465802)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    01/09/2019
    Initiation :
    12/26/2011
    Primary completion :
    05/18/2015
    Completion :
    05/18/2015
    HER-2
    |
    HER-2 amplification • HER-2 mutation
    |
    Vizimpro (dacomitinib)
    Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung (NCT00818441)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    01/08/2019
    Initiation :
    03/11/2009
    Primary completion :
    04/27/2012
    Completion :
    04/30/2015
    EGFR • HER-2
    |
    EGFR mutation • HER-2 amplification
    |
    Vizimpro (dacomitinib)
    Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (M13DAP) (NCT02039336)
    Phase 1/2
    The Netherlands Cancer Institute
    Unknown status
    Last update posted :
    08/27/2018
    Initiation :
    01/01/2014
    Primary completion :
    12/01/2018
    Completion :
    12/01/2019
    KRAS
    |
    KRAS exon 2 mutation
    |
    docetaxel • Vizimpro (dacomitinib) • Gomekli (mirdametinib)
    PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (NCT01112527)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    08/16/2018
    Initiation :
    04/01/2010
    Primary completion :
    09/01/2015
    Completion :
    09/01/2015
    EGFR
    |
    EGFR amplification
    |
    Vizimpro (dacomitinib)
    ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (NCT01360554)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    05/24/2017
    Initiation :
    06/16/2011
    Primary completion :
    09/30/2013
    Completion :
    09/14/2015
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    erlotinib • Vizimpro (dacomitinib)
    PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC) (NCT01152853)
    Phase 2
    Seoul National University Hospital
    Completed
    Last update posted :
    11/20/2015
    Initiation :
    07/01/2010
    Primary completion :
    07/01/2011
    Completion :
    09/01/2012
    HER-2
    |
    HER-2 positive
    |
    cisplatin • Vizimpro (dacomitinib)
    A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer (NCT01121575)
    Phase 1
    Pfizer
    Completed
    Last update posted :
    10/28/2015
    Initiation :
    08/01/2010
    Primary completion :
    02/01/2014
    Completion :
    02/01/2014
    EGFR • HER-2 • KRAS • ALK • PIK3CA • MET • ROS1
    |
    KRAS mutation • EGFR mutation • HER-2 amplification • PIK3CA mutation • MET amplification • EGFR amplification • ALK rearrangement • EGFR mutation + PIK3CA mutation • ALK amplification • ALK rearrangement + PIK3CA mutation
    |
    Xalkori (crizotinib) • Vizimpro (dacomitinib)
    A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen (NCT00769067)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    10/07/2015
    Initiation :
    11/01/2008
    Primary completion :
    10/01/2010
    Completion :
    08/01/2014
    EGFR • KRAS
    |
    erlotinib • Vizimpro (dacomitinib)
    A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT01484847)
    Phase N/A
    University Health Network, Toronto
    Completed
    Last update posted :
    07/10/2015
    Initiation :
    12/01/2011
    Primary completion :
    03/01/2013
    Completion :
    07/01/2015
    EGFR
    |
    Vizimpro (dacomitinib)
    Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment (NCT01116843)
    Phase 1/2
    University Health Network, Toronto
    Completed
    Last update posted :
    07/10/2015
    Initiation :
    05/01/2010
    Primary completion :
    02/01/2012
    Completion :
    02/01/2014
    EGFR • CD44
    |
    EGFR mutation • EGFR amplification • EGFR expression • CD44 expression
    |
    Vizimpro (dacomitinib)